GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma completes acquisition of Lannett Company, Inc., USA

M&A ▲ Positive Development LOW RISK
📅 Filed on BSE: 30 Jun 2026, 09:54 AM IST  ·  BSE ID: 246ff570-c1c2-400d-b7dd-407bba452288
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma's US subsidiary has completed buying Lannett Company, Inc., making it a new part of their business.
🤖 AI Summary
  • Aurobindo Pharma USA Inc. completed the acquisition of Lannett Company, Inc., USA.
  • Lannett officially became a wholly owned subsidiary of APUSA, effective June 29, 2026.
  • Lannett will operate as Lannett Company LLC under Aurobindo Pharma USA Inc.
  • More than 400 Lannett employees have been welcomed into the Aurobindo Pharma USA Inc. organization.
🏢 How This Affects the Company
📈
Business Impact
The acquisition expands Aurobindo Pharma's presence and product portfolio in the US market through Lannett Company LLC.
⚙️
Operational Impact
The integration process will commence immediately, combining capabilities and resources and adding over 400 new employees to Aurobindo Pharma USA Inc.
👥 What This Means For Shareholders
✅
Action Required
No direct action is required by shareholders based on this acquisition completion intimation.
👤
Who Is Affected
Shareholders of Aurobindo Pharma Ltd will be affected as the company's US operations expand through the addition of Lannett Company LLC.
🔍
Management Signal
The completion signals management's commitment to strategic expansion and strengthening its presence in the US pharmaceutical market.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Future financial results — assess contribution from Lannett Company LLC operations.
Management commentary — obtain details on integration progress and synergies.
Market updates — track any further announcements regarding the combined entity's US operations.
LOW RISK The filing confirms a completed acquisition, indicating reduced execution risk.
💡 Investor Takeaway
Aurobindo Pharma USA Inc. completed its acquisition of Lannett Company, Inc., USA, effective June 29, 2026, following US FTC approval. Lannett, with over 400 employees, now operates as Lannett Company LLC, a wholly owned subsidiary.
⚖️ Strengths & Concerns

✅ Positives

  • Successful completion of the acquisition strengthens Aurobindo Pharma USA Inc.'s market position in the US pharmaceutical sector.
  • Integration of over 400 Lannett employees enhances Aurobindo Pharma USA Inc.'s talent base and operational capabilities.
📅 Company Track Record
Aurobindo Pharma had previously intimated receipt of necessary approvals from the US Federal Trade Commission on June 19, 2026, for this Lannett acquisition, with closure expected in June 2026. This filing confirms the completion within the anticipated timeframe.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What event did Aurobindo Pharma Ltd disclose on June 30, 2026?
Aurobindo Pharma Ltd disclosed the successful completion of the acquisition of Lannett Company, Inc., USA, by its wholly owned subsidiary, Aurobindo Pharma USA Inc.
When did Lannett Company, Inc. become a subsidiary of Aurobindo Pharma USA Inc.?
Lannett Company, Inc. became a wholly owned subsidiary of Aurobindo Pharma USA Inc. effective June 29, 2026, and will operate as Lannett Company LLC.
How many employees from Lannett are joining Aurobindo Pharma USA Inc.?
More than 400 Lannett employees are being welcomed into the Aurobindo Pharma USA Inc. organization as part of the acquisition.
What regulatory approval was received for the Lannett acquisition?
Approval from the U.S. Federal Trade Commission was received on June 18, 2026, prior to the acquisition's completion.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.